Nanobiotix S.A. NBTX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -85.02% | -83.75% | 128.97% | 128.21% | 326.50% |
| Total Other Revenue | 14.34% | 24.05% | 4.81% | 2.07% | -42.32% |
| Total Revenue | -78.64% | -76.83% | 139.46% | 138.43% | 202.38% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -78.64% | -76.83% | 139.46% | 138.43% | 202.38% |
| SG&A Expenses | -2.43% | 5.86% | 1.98% | -0.69% | 10.07% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.84% | 1.07% | -31.79% | -33.58% | -17.00% |
| Operating Income | -2,353.60% | -2,545.20% | 71.45% | 72.20% | 103.65% |
| Income Before Tax | -553.18% | -608.66% | 56.18% | 57.33% | 73.91% |
| Income Tax Expenses | 173.53% | 193.75% | 92.58% | 92.37% | -95.61% |
| Earnings from Continuing Operations | -552.76% | -608.19% | 56.14% | 57.29% | 74.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -552.76% | -608.19% | 56.14% | 57.29% | 74.05% |
| EBIT | -2,353.60% | -2,545.20% | 71.45% | 72.20% | 103.65% |
| EBITDA | -1,221.96% | -1,317.24% | 71.54% | 72.29% | 107.49% |
| EPS Basic | -533.39% | -587.27% | 56.89% | 58.02% | 74.22% |
| Normalized Basic EPS | -413.99% | -457.88% | 60.35% | 61.41% | 72.41% |
| EPS Diluted | -533.39% | -587.27% | 56.74% | 57.87% | 74.22% |
| Normalized Diluted EPS | -413.99% | -457.88% | 60.35% | 61.41% | 72.41% |
| Average Basic Shares Outstanding | 3.09% | 3.09% | 1.72% | 1.72% | 0.62% |
| Average Diluted Shares Outstanding | 3.09% | 3.09% | 1.72% | 1.72% | 0.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |